Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis

Journal of the American Society of Nephrology

Volumn 10, Issue 6, 1999, Pages 1253-1263

  Cordonnier, Daniel J ^a   Pinel, Nicole ^d   Barro, Claire ^d   Maynard, Claire ^a   Zaoui, Philippe ^a   Halimi, Serge ^a   De Ligny, Bruno Hurault ^b   Reznic, Yves ^b   Simon, Dominique ^c   Bilous, Rudolf W ^d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier Universitaire   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 0033065531     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v1061253     Document Type: Article

References (49)

1. Raine AEG: Epidemiology, development and treatment of end stage renal failure in non insulin dependent diabetics in Europe. Diabetologia 36: 1099-1104, 1993
2. Pugh JA, Medina RA, Cornell JC, Basu S: NIDDM is the major cause of diabetic end stage renal disease. Diabetes 44: 1375-1380, 1995
3. Barnes DJ, Pinto JR, Viberti JC: The patient with diabetes mellitus. In: Oxford Textbook of Clinical Nephrology, 2nd Ed., edited by Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E, Winearls CG, Oxford, Oxford University Press, 1998, pp 723-775
4. Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non insulin-dependent diabetic patients. Kidney Int 41: 758-762, 1992
5. Gambara V, Mecca G, Remuzzi G, Bertani T: Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 3: 1458-1466, 1993
6. Cordonnier DJ: Glomerular involvement in type II diabetes: Is it all diabetic glomerulosclerosis? [Editorial Comments] Nephrol Dial Transplant 11: 936-938, 1996
7. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 156: 286-289, 1996
8. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Menge MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of Enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 45[Suppl 451]: S150-S155, 1994
9. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641-1650, 1996
10. Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E: Contrasting effect of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non insulin dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 8: 793-798, 1997
11. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82: 5963-5967, 1985
12. Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A: Structure and function of the kidney in diabetic glomerulosclerosis. Pathol Res Pract 167: 204-216, 1980
13. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5: 1273-1287, 1994
14. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 49: 578-597, 1996
15. Fioretto P, Steffes MW, Sutherland DER, Mauer M: Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. Kidney Int 48: 1929-1935, 1995
16. Taft J, Nolan CJ, Yeung SP, Hewitson TD, Martin FIR: Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43: 1046-1051, 1994
17. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057, 1979
18. Weibel ER: Principles and methods for the morphometric study of the lung and other organs. Lab Invest 12: 131-135, 1963
19. Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43-661-667, 1993
20. Ellis EN, Basgen JM, Mauer SM, Steffes MW: Kidney biopsy technique and evaluation. In: Methods in Diabetes Research, Vol. II, edited by Clarke WL, Larner J, Pohl SL, New York, John Wiley and Sons, 1986
21. Cushman CW, Cheung HS: Spectrometric assay and properties of the angiotensin converting enzyme of rabbit lung. Biochem Pharmacol 20: 1637-1648, 1983
22. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatelier G, Sert C, Dusselier L, Kahal Z: Contribution of genetic polymorphism in the renin angiotensin system to the development of renal complications in insulin-dependent diabetes. Génétique de la néphropathie diabétique GENEDIAB Study Group. J Clin Invest 99: 1585-1595, 1997
23. Guasch A, Hashimoto H, Sibley RK, Deen WM, Myers BD: Glomerular dysfunction in nephrotic humans with minimal changes or focal glomerulosclerosis. Am J Physiol 260: F728-F737, 1991
24. Sokal RR, Rohlf FJ: Estimation and hypothesis testing. In: Biometry: The Principles and Practice of Statistics in Biological Research, 2nd Ed., edited by Freeman WH, New York, The Maple-Vail Book Manufacturing Group, 1981, pp 128-175
25. Koch GG, Edwards S: Clinical efficacy trials with categorical data: The Mantel-Haenszel method. In: Biopharmaceutical Statistics for Drug Development, edited by Reace KE, New York, Marcel Dekker, 1988, pp 415-418
26. Schainuck LI, Striker GE, Cutler RE: Structural functional correlations in renal disease. Part II. The correlations. Hum Pathol 1: 631-640, 1970
27. Mackensen-Haen S, Eissele R, Bohle A: Contribution on the correlation between morphometric parameters gained from the renal cortex and renal function in IgA nephritis. Lab Invest 59: 239-244, 1988
28. Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G: Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 2: 220-228, 1994
29. Thomsen O, Andersen A, Sandahl-Christiansen J, Deckert T: Renal changes in long term type I (insulin-dependent) diabetic patients with and without clinical nephropathy: A light microscopic, morphometric study of an autopsy material. Diabetologia 24: 361-365, 1984
30. Suzuki Y, Ueno M, Hayashi H, Nishi S, Satou H, Karasawa R, Inn H, Suzuki S, Maruyama Y, Arakawa M: A light microscopic study of glomerulosclerosis in Japanese patients with non insulin-dependent diabetes mellitus: The relationship between clinical and histological features. Clin Nephrol 42: 155-162, 1994
31. U.S. Renal Data System: USRDS: Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, April 1997, p 31
32. Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics: Three year analysis. Hypertension 21 6: 786-794, 1993
33. Nielsen F, Rossing P, Gall M-A, Skott P, Smidt U, Parving H: Impact of Lisinopril and Atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 43: 1108-1113, 1994
34. Nerlich A, Schleicher E, Wiest I, Specks U, Timpl R: Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int 45: 1648-1656, 1994
35. McGregor B, Colon S, Mutin M, Chignier E, Zech P, McGregor J: Thrombospondin in human glomerulopathies: A marker of inflammation and early fibrosis. Am J Pathol 144: 1281-1287, 1994
36. Wolf G, Neilson EG, Goldfarb S, Ziyadeh F: The influence of glucose concentration on angiotensin II-induced hypertrophy of proximal tubular cells in culture. Biochem Biophys Res Commun 176: 902-909, 1991
37. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy Kidney Int 40: 1007-1012, 1991
38. Rodemann H, Muller G: Characterization of human renal fibroblasts in health and disease: In vitro growth, differentiation and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 17: 684-686, 1991
39. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5: 1492-1497, 1995
40. Nerlich A, Schleicher E: Immunohistochemical localization of extracellular components in human diabetic glomerular lesions. Am J Pathol 139: 889-899, 1991
41. Bangstadt HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF: Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37: 483-490, 1994
42. Barbosa J, Steffes MW, Sutherland DER, Connett JE, Mauer S: Effect of glycemic control on early diabetic renal lesions. JAMA 272: 600-606, 1994
43. Agardh C, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett A: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10: 185-192, 1996
44. Romero R, Salinas I, Lucas A, Teixido J, Audi L, Sanmarti A: Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract 17: 191-198, 1992
45. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 302: 210-216, 1991
46. Chan J, Cockram C, Nicholls M, Cheung C, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. Br Med J 305: 981-985, 1992
47. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39: 1569-1576, 1996
48. Pinel N, Fadel B, Bilous RW, Corticelli P, Halimi S, Cordonnier D: Renal biopsies in 30 micro and macroalbuminuric non-insulin dependent (NIDDM) type 2 patients: Heterogeneity of renal lesions [Abstract], Nephrol Dial Transplant 10: 978, 1995
49. Ruggenenti P, Mosconi L, Bianchi L, Cortesi L, Campana M, Pagani G, Mecca G, Remuzzi G: Long term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 24: 753-761, 1994